Ischemia-modified albumin: is it a promising marker in acute coronary syndrome?

DOI: https://doi.org/10.1186/s12872-024-04108-2
IF: 2.174
2024-08-25
BMC Cardiovascular Disorders
Abstract:Acute coronary syndrome (ACS) is a type of coronary heart disease (CHD), which is responsible for one-third of total deaths in people older than 35 years. Even though cardiac troponin is the gold standard for myocardial necrosis it is blind for ischemia without necrosis. Studies demonstrate that Ischaemia Modified Albumin (IMA) is more sensitive in diagnosing ischemic chest pain compared to cardiac troponin T and electrocardiogram, and its combination with these tests significantly increases the sensitivity for diagnosing unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI), with high positive and negative predictive values, making it a valuable tool for ruling out ACS in patients with inconclusive diagnoses in the emergency department.
cardiac & cardiovascular systems
What problem does this paper attempt to address?